BACKGROUND: MicroRNAs (miRNAs) may function as suppressors or promoters of tumor metastasis according to their messenger RNA targets. Previous studies have suggested that miR-9 and miR-151-5p are associated with metastasis in breast cancer and hepatocellular carcinoma, respectively. We aimed to further establish the potential roles of miR-9 and miR-151-5p in tumor invasion and metastasis and investigate their use as biomarkers. METHODS: We used quantitative real-time PCR (qRT-PCR) to measure differences in miR-9 and miR-151-5p expression between primary breast tumors and their lymph-node metastases in 194 paired tumor samples from 97 patients. We also correlated expression levels with histologic data to investigate their utility as biomarkers. RESULTS: There were no significant differences in miR-9 expression between the primary tumors and lymph nodes; however, miR-151-5p expression was significantly lower in the lymph-node metastases than in their corresponding tumors (p < 0.05). miR-9 levels were elevated in primary breast tumors from patients diagnosed with higher-grade tumors (p < 0.05); however, no differences were observed in miR-151-5p levels between different grades of tumor. Interestingly, miR-9 levels were elevated in invasive lobular carcinomas (ILC) compared with invasive ductal carcinomas (IDC; p < 0.01). CONCLUSIONS: In aggregate, these data suggest that miR-151-5p upregulation may suppress metastasis in primary breast tumors. Both miRNAs may serve as useful biomarkers in future clinical trials in breast cancer.
BACKGROUND: MicroRNAs (miRNAs) may function as suppressors or promoters of tumor metastasis according to their messenger RNA targets. Previous studies have suggested that miR-9 and miR-151-5p are associated with metastasis in breast cancer and hepatocellular carcinoma, respectively. We aimed to further establish the potential roles of miR-9 and miR-151-5p in tumor invasion and metastasis and investigate their use as biomarkers. METHODS: We used quantitative real-time PCR (qRT-PCR) to measure differences in miR-9 and miR-151-5p expression between primary breast tumors and their lymph-node metastases in 194 paired tumor samples from 97 patients. We also correlated expression levels with histologic data to investigate their utility as biomarkers. RESULTS: There were no significant differences in miR-9 expression between the primary tumors and lymph nodes; however, miR-151-5p expression was significantly lower in the lymph-node metastases than in their corresponding tumors (p < 0.05). miR-9 levels were elevated in primary breast tumors from patients diagnosed with higher-grade tumors (p < 0.05); however, no differences were observed in miR-151-5p levels between different grades of tumor. Interestingly, miR-9 levels were elevated in invasive lobular carcinomas (ILC) compared with invasive ductal carcinomas (IDC; p < 0.01). CONCLUSIONS: In aggregate, these data suggest that miR-151-5p upregulation may suppress metastasis in primary breast tumors. Both miRNAs may serve as useful biomarkers in future clinical trials in breast cancer.
Authors: Marilena V Iorio; Manuela Ferracin; Chang-Gong Liu; Angelo Veronese; Riccardo Spizzo; Silvia Sabbioni; Eros Magri; Massimo Pedriali; Muller Fabbri; Manuela Campiglio; Sylvie Ménard; Juan P Palazzo; Anne Rosenberg; Piero Musiani; Stefano Volinia; Italo Nenci; George A Calin; Patrizia Querzoli; Massimo Negrini; Carlo M Croce Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2004-02-18 Impact factor: 11.205
Authors: Amaia Lujambio; George A Calin; Alberto Villanueva; Santiago Ropero; Montserrat Sánchez-Céspedes; David Blanco; Luis M Montuenga; Simona Rossi; Milena S Nicoloso; William J Faller; William M Gallagher; Suzanne A Eccles; Carlo M Croce; Manel Esteller Journal: Proc Natl Acad Sci U S A Date: 2008-09-03 Impact factor: 11.205
Authors: Scott Valastyan; Ferenc Reinhardt; Nathan Benaich; Diana Calogrias; Attila M Szász; Zhigang C Wang; Jane E Brock; Andrea L Richardson; Robert A Weinberg Journal: Cell Date: 2009-06-12 Impact factor: 41.582
Authors: Espen Enerly; Israel Steinfeld; Kristine Kleivi; Suvi-Katri Leivonen; Miriam R Aure; Hege G Russnes; Jo Anders Rønneberg; Hilde Johnsen; Roy Navon; Einar Rødland; Rami Mäkelä; Bjørn Naume; Merja Perälä; Olli Kallioniemi; Vessela N Kristensen; Zohar Yakhini; Anne-Lise Børresen-Dale Journal: PLoS One Date: 2011-02-22 Impact factor: 3.240
Authors: Kelly N Holohan; Debomoy K Lahiri; Bryan P Schneider; Tatiana Foroud; Andrew J Saykin Journal: Front Genet Date: 2013-01-17 Impact factor: 4.599
Authors: Meng-Lay Lin; Hetal Patel; Judit Remenyi; Christopher R S Banerji; Chun-Fui Lai; Manikandan Periyasamy; Ylenia Lombardo; Claudia Busonero; Silvia Ottaviani; Alun Passey; Philip R Quinlan; Colin A Purdie; Lee B Jordan; Alastair M Thompson; Richard S Finn; Oscar M Rueda; Carlos Caldas; Jesus Gil; R Charles Coombes; Frances V Fuller-Pace; Andrew E Teschendorff; Laki Buluwela; Simak Ali Journal: Oncotarget Date: 2015-08-28